NDAQ:AKRO) Class Action Announcement for Akero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc.

Tim Rolph, D.Phil., Chief Scientific Officer and Co-Founder of Akero Therapeutics, a company devoted to developing novel therapies for patients with serious metabolic diseases, including efruxifermin, ...

May 14, 2024) - The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action ...

BofA Securities raised the price target for the Akero Therapeutics Inc (NASDAQ:AKRO) stock to “a Neutral”. The rating was released on April 22, 2024, according to finviz. The research report from UBS ...

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), retaining the price target of ...

Stockholders' Equity: Grew to $846.25 million, up from $535.31 million at the end of the previous year.

If you suffered losses exceeding $75,000 investing in Akero stock or options between September 13, 2022 and October 9, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner ...

BofA Securities raised the price target for the Akero Therapeutics Inc (NASDAQ:AKRO) stock to “a Neutral”. The rating was released on April 22, 2024, according to finviz. The research report from UBS ...

Akero Therapeutics (NASDAQ:AKRO) just reported results for the first quarter of 2024. Akero Therapeutics reported earnings per share of -90 cents. This was above the analyst estimate for EPS of -95 ...

On October 10, 2023, Akero announced the results of its Phase 2b SYMMETRY trial, revealing that the study had failed to meet its primary endpoint. On this news, Akero's stock price fell $30.39, or ...

Q1 GAAP EPS of -$0.90 beats by $0.05. Akero's cash, cash equivalents and short-term marketable securities as of March 31, ...

Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported ...